Highlights Newsletter 1
This newsletter presents you the following key sessions:
4. 177Lu-PSMA-617 outperforms cabazitaxel in men with metastatic castration-resistant prostate cancer
This newsletter presents you the following key sessions:
4. 177Lu-PSMA-617 outperforms cabazitaxel in men with metastatic castration-resistant prostate cancer
Medical writer
Medical writer